Cellectricon, a services provider dedicated to advancing neuroscience drug discovery, announced the launch of its new Neurotoxicity Testing Services; expanding its established neuroscience discovery platform to support the early safety assessment of drug candidates. Reflecting growing interest and feedback from the neuroscience community, the new service empowers drug developers to detect potential neurotoxic effects sooner—reducing risk, saving time, and improving confidence in candidate selection.

The new Neurotoxicity Testing Services draw directly on Cellectricon’s longstanding neuroscience expertise and portfolio of validated in vitro models. Clients can benefit from assays integrating optical electrophysiology, high-content imaging, and microfluidic systems. The result is an ability to evaluate a broad range of acute and chronic neurotoxicity endpoints; including neuronal excitability, neurite outgrowth, metabolic activity, cytokine release, and cellular phenotype.

By combining these advanced technologies with high-capacity assay formats, Cellectricon empowers drug developers to front-load safety evaluation across diverse therapeutic modalities—enabling the identification of neurotoxic effects earlier in the discovery pipeline.

“In recent years, we’ve seen growing demand for early-stage neurotoxicity testing—particularly from teams developing oligonucleotide-based drugs, who often face challenges in obtaining reliable, accurate assessments.” said Mattias Karlsson, Chief Executive Officer at Cellectricon. “We recognized that our existing validated assays were exceptionally well suited to address these needs. By building on our trusted assays and in vitro models, we’re proud to offer a robust solution that helps our clients make safer, faster decisions with greater confidence.”